| 1. |
Machens A, Lorenz K, Sekulla C, et al. Molecular epidemiology of multiple endocrine neoplasia 2: implications for RET screening in the new millenium. Eur J Endocrinol, 2013, 168(3): 307-314.
|
| 2. |
Znaczko A, Donnelly DE, Morrison PJ. Epidemiology, clinical features, and genetics of multiple endocrine neoplasia type 2B in a complete population. Oncologist, 2014, 19(12): 1284-1286.
|
| 3. |
Opsahl EM, Brauckhoff M, Schlichting E, et al. A nationwide study of multiple endocrine neoplasia type 2A in norway: predictive and prognostic factors for the clinical course of medullary thyroid carcinoma. Thyroid, 2016, 26(9): 1225-1238.
|
| 4. |
Mathiesen JS, Kroustrup JP, Vestergaard P, et al. Incidence and prevalence of multiple endocrine neoplasia 2B in Denmark: a nationwide study. Endocr Relat Cancer, 2017, 24(7): L39-L42.
|
| 5. |
Mathiesen JS, Kroustrup JP, Vestergaard P, et al. Incidence and prevalence of multiple endocrine neoplasia 2A in Denmark 1901-2014: a nationwide study. Clin Epidemiol, 2018, 10: 1479-1487.
|
| 6. |
Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid, 2015, 25(6): 567-610.
|
| 7. |
Fassnacht M, Assie G, Baudin E, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2020, 31(11): 1476-1490.
|
| 8. |
Janssen I, Chen CC, Millo CM, et al. PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging, 2016, 43(10): 1784-1791.
|
| 9. |
Mathiesen JS, Effraimidis G, Rossing M, et al. Multiple endocrine neoplasia type 2: a review. Semin Cancer Biol, 2022, 79: 163-179.
|
| 10. |
Iihara M, Yamashita T, Okamoto T, et al. A nationwide clinical survey of patients with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma in Japan. Jpn J Clin Oncol, 1997, 27(3): 128-134.
|
| 11. |
Modigliani E, Vasen HM, Raue K, et al. Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The Euromen Study Group. J Intern Med, 1995, 238(4): 363-367.
|
| 12. |
Howe JR, Norton JA, Wells SA Jr. Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up. Surgery, 1993, 114(6): 1070-1077.
|
| 13. |
Machens A, Brauckhoff M, Holzhausen HJ, et al. Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab, 2005, 90(7): 3999-4003.
|
| 14. |
Quayle FJ, Fialkowski EA, Benveniste R, et al. Pheochromocytoma penetrance varies by RET mutation in MEN 2A. Surgery, 2007, 142(6): 800-805.
|
| 15. |
Imai T, Uchino S, Okamoto T, et al. High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients. Eur J Endocrinol, 2013, 168(5): 683-687.
|
| 16. |
Rodriguez JM, Balsalobre M, Ponce JL, et al. Pheochromocytoma in MEN 2A syndrome. Study of 54 patients. World J Surg, 2008, 32(11): 2520-2526.
|
| 17. |
Kotecka-Blicharz A, Hasse-Lazar K, Jurecka-Lubieniecka B, et al. Occurrence of phaeochromocytoma tumours in RET mutation carriers - a single-centre study. Endokrynol Pol, 2016, 67(1): 54-58.
|
| 18. |
Frank-Raue K, Rybicki LA, Erlic Z, et al. Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Hum Mutat, 2011, 32(1): 51-58.
|
| 19. |
Machens A, Elwerr M, Lorenz K, et al. 100-year evolution of precision medicine and surgery for multiple endocrine neoplasia type 2A. Endocrine, 2020, 68(2): 368-376.
|
| 20. |
Uchino S. Multiple endocrine neoplasia type 2 in Japan: large-scale analysis of data from the MEN consortium of Japan. Nihon Geka Gakkai Zasshi, 2012, 113(4): 362-367.
|
| 21. |
Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet, 1993, 2(7): 851-856.
|
| 22. |
Raue F, Frank-Raue K. Genotype-phenotype correlation in multiple endocrine neoplasia type 2. Clinics (Sao Paulo), 2012, 67(Suppl 1): 69-75.
|
| 23. |
Febrero B, Rodríguez JM, Ríos A, et al. Prophylactic thyroidectomy in multiple endocrine neoplasia 2 (MEN2) patients with the C634Y mutation: a long-term follow-up in a large single-center cohort. Eur J Surg Oncol, 2019, 45(4): 625-630.
|
| 24. |
Castinetti F, Eng C. Genotype/phenotype correlations in multiple endocrine neoplasia type 2. Endocr Relat Cancer, 2024, 31(12): e240139.
|
| 25. |
Kumar A, Pappachan JM, Fernandez CJ. Catecholamine-induced cardiomyopathy: an endocrinologist’s perspective. Rev Cardiovasc Med, 2021, 22(4): 1215-1228.
|
| 26. |
Kassim TA, Clarke DD, Mai VQ, et al. Catecholamine-induced cardiomyopathy. Endocr Pract, 2008, 14(9): 1137-1149.
|
| 27. |
Zelinka T, Petrák O, Turková H, et al. High incidence of cardiovascular complications in pheochromocytoma. Horm Metab Res, 2012, 44(5): 379-384.
|
| 28. |
Lopes LR, Ho CY, Elliott PM. Genetics of hypertrophic cardiomyopathy: established and emerging implications for clinical practice. Eur Heart J, 2024, 45(30): 2727-2734.
|
